Format

Send to

Choose Destination
Curr Drug Targets. 2019 Jun 18. doi: 10.2174/1389450120666190618125100. [Epub ahead of print]

High Mobility Group Box-1 (HMGB1): A potential target in therapeutics.

Author information

1
Department of Pharmacology, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Mumbai. India.
2
Department of Pharmacology, Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (West), Mumbai, 400056. India.

Abstract

High mobility group box-1 (HMGB1) mainly belongs to the non-histone DNA-binding protein. It has been studied as a nuclear protein that is present in eukaryotic cells. From the HMG family, HMGB1 protein has been focused particularly for its pivotal role in several pathologies. HMGB-1 is considered as an essential facilitator in diseases such as sepsis, collagen disease, atherosclerosis, cancers, arthritis, acute lung injury, epilepsy, myocardial infarction, and local and systemic inflammation. Modulation of HMGB1 levels in the human body provides a way in the management of these diseases. Various strategies, such as HMGB1-receptor antagonists, inhibitors of its signalling pathway, antibodies, RNA inhibitors, vagus nerve stimulation etc. have been used to inhibit expression, release or activity of HMGB1. This review encompass role of HMGB1 in various pathologies and discuss its therapeutic potential in these pathologies.

KEYWORDS:

Cancer; Cytokine mediator; High mobility group box-1; Inflammatory disease; Sepsis

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center